Abstract Library

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4475 Retreatment with [177Lu]Lu-DOTATATE in neuroendocrine tumours: Outcomes in progression-free survival and toxicity – Our experience

Introduction: Multiple systemic treatments exist for advanced or metastatic NETs, including somatostatin analogues, targeted agents, chemotherapy, and peptide receptor radionuclide therapy (PRRT). PRRT has shown maximum benefit for response rate, progression-free survival (PFS), and overall survival (OS) with favourable toxicity.

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Mari Hualde A, Ardila Manjarés E, Guzman Cruz A, Orcajo Rincón J,

Keywords: Neuroendocrine tumour (NET), Peptide receptor radionuclide therapy (PRRT), [177Lu]Lu-DOTATATE, Retreatment (R-PRRT), Toxicity, Progression-free survival (PFS), Overall survival (OS),

#3534 Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Translational results from NET-001 and NET-002 trials

Introduction: The role of immunotherapy (IO) and predictive biomarkers in NENs patients remains unclear.

Conference:

Presenting Author: Rodriguez Freixinos V

Authors: Rodriguez-Freixinos V, Bruce J, Chan D, Nunez-Rodriguez J, Mackenzie D,

Keywords: neuroendocrine, cell, research, immunotherapy,

#2948 Efficacy Prediction Using Computed Tomography for Patients with Pancreatic Neuroendocrine Tumors Receiving Sunitinib

Introduction: How to predict the efficacy of sunitinib before treatment initiation was less known.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zhang Y, Chen L, Wang W, Jin K, Yuan B,

Keywords: sunitinib, computed tomography, efficacy prediction,

#2782 Clinical Efficacy of Peptide Receptor Radionuclide Therapy in Patients with Neuroendocrine Neoplasm

Introduction: Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic neuroendocrine neoplasms (NEN) with positive effects on both progression free survival (PFS) and overall survival (OS). Only a few previous studies have investigated the effect of a second series and hence a retreatment with PRRT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Zacho M, Iversen P, Villadsen G, Arveschoug A, Grønbæk H,

Keywords: neuroendocrine tumor, gastropancreatic tumors, bronchopulmonary tumors, peptide receptor radionuclide therapy,